Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

References

• OrlandoRCThe pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposureAm J Gastroenterol199792Suppl 43S5S discussion 5S–7S9127620
   PubMed Web of Science ®Google Scholar
• NelsonSPChenEHSyniarGMChristoffelKKPrevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research GroupArch Pediatr Adolesc Med2000154215015410665601
   PubMedGoogle Scholar
• GilgerMAEl-SeragHBGoldBDPrevalence of endoscopic findings of erosive esophagitis in children: a population-based studyJ Pediatr Gastroenterol Nutr200847214114618664864
   PubMed Web of Science ®Google Scholar
• CezardJPManaging gastro-oesophageal reflux disease in childrenDigestion200469Suppl 13815001829
   PubMed Web of Science ®Google Scholar
• VandenplasYRudolphCDDi LorenzoCPediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)J Pediatr Gastroenterol Nutr200949449854719745761
   PubMed Web of Science ®Google Scholar
• El-SeragHBGilgerMKuebelerMRabeneckLExtraesophageal associations of gastroesophageal reflux disease in children without neurologic defectsGastroenterology200112161294129911729108
   PubMed Web of Science ®Google Scholar
• GoldBDGunasekaranTToliaVSafety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux diseaseJ Pediatr Gastroenterol Nutr200745552052918030228
   PubMed Web of Science ®Google Scholar
• ToliaVBishopPRTsouVMGremseDSofferEFComer GM; Members of the 322 Study GroupMulticenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5–11 years) with symptomatic gastroesophageal reflux diseaseJ Pediatr Gastroenterol Nutr200642438439116641576
   PubMed Web of Science ®Google Scholar
• FiedorekSToliaVGoldBDEfficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux diseaseJ Pediatr Gastroenterol Nutr200540331932715735486
   PubMed Web of Science ®Google Scholar
• HassallEIsraelDShepherdROmeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study GroupJ Pediatr2000137680080711113836
   PubMed Web of Science ®Google Scholar
• ToliaVFerryGGunasekaranTHuangBKeithRBookLEfficacy of lansoprazole in the treatment of gastroesophageal reflux disease in childrenJ Pediatr Gastroenterol Nutr200235Suppl 4S308S31812607791
   PubMed Web of Science ®Google Scholar
• ToliaVFitzgeraldJHassallEHuangBPilmerBKaneRSafety of lansoprazole in the treatment of gastroesophageal reflux disease in childrenJ Pediatr Gastroenterol Nutr200235Suppl 4S300S30712607790
   PubMed Web of Science ®Google Scholar
• DEXILANT (dexlansoprazole) delayed-release capsules [prescribing information]Deerfield, ILTakeda Pharmaceuticals America, Inc2013 Available from: www.takeda.us/products/default.aspxAccessed September 29, 2014
   Google Scholar
• PeuraDAMetzDCDabholkarAHParisMMYuPAtkinsonSNSafety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experienceAliment Pharmacol Ther200930101010102119735233
   PubMed Web of Science ®Google Scholar
• KukulkaMWuJPerezMCPharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERDJ Pediatr Gastroenterol Nutr2012541414721716130
   PubMed Web of Science ®Google Scholar
• GremseDWinterHToliaVPharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux diseaseJ Pediatr Gastroenterol Nutr200235Suppl 4S319S32612607792
   PubMed Web of Science ®Google Scholar
• KuczmarskiRJOgdenCLGuoSS2000CDC Growth Charts for the United States: methods and developmentVital Health Stat20022461190
   Google Scholar
• World Medical AssociationWMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human SubjectsFerney-Voltaire, FranceWorld Medical Associatin amended October 2013. Available from: http://www.wma.net/en/30publications/10policies/b3/index.html.pdf?print-media-type&footer-right=[page]/[toPage]Accessed September 29, 2014
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseICH Harmonised Tripartite Guideline - Guideline for Good Clinical PracticeGeneva, Switzerland revised 10 June 1996. Availabe from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdfAccessed September 29, 2014
   Google Scholar
• VakilyMZhangWWuJAtkinsonSNMulfordDPharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trialsCurr Med Res Opin200925362763819232037
   PubMed Web of Science ®Google Scholar
• LeePRudolphCGastroesophageal reflux in infants and childrenAdv Pediatr20014830132911480761
   PubMedGoogle Scholar
• ZannikosPNDooseDRLeitzGJPharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux diseaseJ Pediatr Gastroenterol Nutr201152669170121478756
   PubMed Web of Science ®Google Scholar
• LindTRydbergLKylebäckAEsomeprazole provides improved acid control vs omeprazole In patients with symptoms of gastrooesophageal reflux diseaseAliment Pharmacol Ther200014786186710886041
   PubMed Web of Science ®Google Scholar
• HuntRHArmstrongDJamesCEffect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteersAm J Gastroenterol200510091949195616128938
   PubMed Web of Science ®Google Scholar
• GunasekaranTGuptaSGremseDLansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerabilityJ Pediatr Gastroenterol Nutr200235Suppl 4S327S33512607793
   PubMed Web of Science ®Google Scholar
• PREVACID^® (lansoprazole) delayed-release capsules, PREVACID^® SoluTab (lansoprazole) delayed-release orally disintegrating tablets [prescribing information]Deerfield, ILTakeda Pharmaceuticals America, Inc2012 Available from: www.takeda.us/products/default.aspxAccessed September 29, 2014
   Google Scholar
• ZhangWWuJAtkinsonSNEffects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjectsJ Clin Pharmacol200949444445419318694
   PubMed Web of Science ®Google Scholar